Image by 7raysmarketing from Pixabay

The cannabis industry was abuzz with a momentous development that could reshape the landscape of medical research, regulatory compliance, and investment. In a groundbreaking move, the Department of Justice (DOJ) and the Drug Enforcement Agency (DEA) have proposed to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). Grasping the full implications of this shift is paramount for investors, operators, and advocates within the cannabis industry.

The Importance of Reschedule

As reported by AP News, the DOJ/DEA is proposing to reschedule cannabis from a Schedule I drug to a Schedule III drug under the CSA. If implemented, it would be a monumental step toward ending the longstanding conflict between federal and state cannabis laws. This move is significant for several reasons:

1. Acknowledgment of Medical Utility: Moving cannabis to Schedule III is a formal recognition by federal authorities recognizing the therapeutic benefits cannabis can offer.
2. Enhanced Research Opportunities: Rescheduling to Schedule III could lead to breakthroughs in understanding the full spectrum of therapeutic properties of cannabis, potentially leading to new medical treatments and better-informed drug policy.
3. Regulatory Relief: Schedule III could reduce the legal ambiguity and operational risks that currently complicate everything from product development to marketing and sales in the cannabis industry.
4. Impact on Criminal Justice: Rescheduling cannabis might trigger a reevaluation of penalties, potentially prompting legislative and judicial actions to adjust sentences or decriminalize certain offenses.
5. Economic Implications: By easing banking restrictions and providing IRS tax burden relief, more investors might be willing to enter the cannabis market, making it more attractive to large institutional investors for job creation and economic growth.
6. Normalization and Destigmatization: Changing its classification can influence public perception, potentially leading to broader acceptance of cannabis both medicinally and recreationally.

Understanding CSA I and III Drug Schedules

Let’s break down what it means to be classified under Schedule I instead of Schedule III. Under the CSA, drugs, substances, and certain chemicals used to make drugs are classified into five distinct categories or schedules depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential. (see DEA.gov).

• Schedule I drugs are classified as having no currently accepted medical use and a high potential for abuse. Examples include heroin, LSD, and, until now, cannabis. This classification has been a significant barrier to research, as it places numerous restrictions and regulatory burdens on handling these substances.
• Schedule III includes drugs that have a potential for abuse less than substances in Schedule I or II and that possess accepted medical uses. This schedule includes products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, and, now potentially, cannabis.

Benefits for Multi-State Operators (MSOs)

Rescheduling cannabis to Schedule III could herald substantial benefits for MSOs in the cannabis industry:

1. Access to Banking Services and Interstate Commerce: Schedule III status can alleviate these concerns and open up interstate cannabis commerce opportunities for MSOs looking to expand operations across state lines more seamlessly.
2. Increased Research Opportunities: This could facilitate the development of new products and allow MSOs to substantiate health claims, which can be pivotal for marketing and consumer education.
3. Tax Benefits: Rescheduling could allow MSOs to claim these deductions, significantly reducing their tax liabilities.
4. Improved Public Perception and Market Expansion: The reclassification would help further destigmatize cannabis and could also influence additional states to consider legalization or expanding their existing cannabis programs.
5. Regulatory Compliance and Licensing: Rescheduling cannabis to Schedule III could facilitate more clinical research and set the stage for eventual Food and Drug Administration (FDA) regulation of cannabis products that has occurred with other Schedule III drugs.

Conclusion

The rescheduling of cannabis to Schedule III could be a significant shift towards the acceptance and understanding of cannabis as a beneficial pharmaceutical and therapeutic product. While the rescheduling change wouldn’t eliminate all legal hurdles, it could potentially set the stage for further reforms in the future.